Plasma TARC outperforms sGalectin-1, sCD163 and sCD30 as a biomarker for treatment response in classical Hodgkin lymphoma

W.J. Plattel, Z.N.D. Alsada, G.W. van Imhoff, A. Glaudemans, A. Diepstra, A. van den Berg, L. Visser

Woensdag 20 april 2016

15:20 - 15:30u in Zaal 0.4

Categorie├źn: Parallelsessie

Parallel sessie: Parallelsessie 3: Case reports/research

Background: Soluble Galectin-1 (sGal-1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of classical Hodgkin lymphoma (cHL) patients. We previously showed that plasma CCL17/Thymus and Activation Regulated Chemokine (TARC) serves as a good biomarker for early treatment response. In the current study we compared the clinical utility of these biomarkers with FDG-PET imaging for cHL response evaluation.

Methods: Serial plasma samples were prospectively collected among 103 newly diagnosed cHL patients. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and treatment response. FDG-PET results were both quantified and visually reassessed according to the Deauville criteria for response evaluation.

Results: Significantly elevated levels of sGal-1, sCD163 and sCD30 were found in 24%, 14% and 60% of cHL patients respectively. Levels of sGal-1 and sCD30 significantly decreased after treatment, but these markers did not correlate with treatment response on individual patient level. In contrast, TARC levels were elevated in 92% of cHL patients and strongly correlated with metabolic tumour volume and treatment response. Elevated levels of TARC during and after treatment correlated with Deauville score 4 or 5.

Conclusion: Elevated levels of sGal-1, sCD163 and sCD30 can be found in patients with cHL. However, plasma TARC was elevated in a much higher proportion of patients and outperformed these markers as a biomarker of cHL treatment response. TARC might serve as a substitute for FDG-PET imaging in future response evaluation.